A small float helped amplify the stock’s swing, turning its IPO into a test of investor sentiment.

The drug developer has no approved products or revenue yet, but the IPO could extend its cash runway by nearly six years.

Its product focus and logistics upgrades have helped lift profitability and operational efficiency.

The listing will test investor appetite for decision intelligence as the AI narrative reaches a high point.

The company leads global RPU shipments by volume.

The planned IPO comes as the memory company expands beyond consumer modules into edge AI and enterprise storage.

The company is moving beyond traditional robots into higher-value systems designed for smart manufacturing.

Cockpit-driving integrated products sit at the center of the company’s pitch.

The company has hired advisors and signed a guidance agreement, but said any RMB share issuance remains preliminary.

The listing bid comes as conversational AI moves deeper into cars, offices, homes, and other everyday settings.